IMPORTANCE A range of somatic driver alterations has been described in estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer (BC); however, the clinical relevance is unknown.
L arge-scale, next-generation sequencing studies have provided valuable insights into the genomic landscape of primary breast cancers (BCs). [1] [2] [3] [4] [5] These studies have highlighted the diverse spectrum of driver alterations and mutational processes in estrogen receptor-positive, HER2-negative (ER+/HER2−) disease, the most commonly diagnosed BC subtype. Despite these findings, the clinical implications of driver alterations including the most frequent-PIK3CA (Entrez 5290) mutations-remains to be fully elucidated.
Women with a diagnosis of early-stage ER+/HER2− BC typically receive adjuvant systemic therapy consisting of endocrine therapy, often preceded by chemotherapy. In addition to markers of anatomic tumor burden, 6 a number of gene expression-based markers exist to aid in estimation of prognosis and decision making regarding adjuvant chemotherapy.
7-9
These markers are based on continuous gene expression variables and the characterization of phenotype resulting from underlying genetic and epigenetic processes. A common theme of gene expression signatures is the observation that higher rates of proliferation portend poorer prognosis.
10
For adjuvant endocrine therapy, the Breast International Group (BIG) 1-98 study was a seminal, phase 3 clinical trial that evaluated the superiority of 5 years of letrozole over tamoxifen in postmenopausal women with early-stage, hormone receptor-positive BC. At a median of 8.1 years' follow-up, 5 years of letrozole treatment demonstrated a significant reduction in the risk of death compared with tamoxifen alone, establishing aromatase inhibition as the standard of care for postmenopausal women with hormone receptor-positive BC.
11-13 Other endocrine therapy options now also exist with the type, sequencing, duration, and possible future incorporation of cyclindependent kinase 4/6 inhibitors as considerations in therapeutic decision making. 14 Clinically useful biomarkers to aid in individualizing these options are lacking.
PIK3CA mutations are particularly enriched in luminal BCs, 1 associated with improved outcomes and sensitivity to endocrine therapy in ER+ BC, 15 and have been shown to be associated with the initiation of ER+ tumors. 16 Therefore, owing to its association with estrogen signaling, we hypothesized that letrozole, being the more potent antiestrogen, would have higher clinical benefit than tamoxifen in patients with tumors harboring PIK3CA mutations. In this study, we aimed to characterize the clinical relevance of oncogenic drivers in postmenopausal patients with early-stage ER+/HER2− BC enrolled in the BIG 1-98 study. Our primary objective was to investigate the prognostic associations of driver alterations with distant recurrence-free interval. As a secondary objective, we evaluated whether PIK3CA mutations could be predictive of a greater magnitude of benefit with letrozole over tamoxifen and hence could have implications for selection of adjuvant endocrine treatment.
Methods
Patients BIG 1-98 was a multicenter, randomized, double-blind, phase 3 trial in which 8010 postmenopausal patients with hormone receptor-positive, operable, invasive BC were randomly assigned to monotherapy with letrozole (2.5 mg orally daily) or tamoxifen (20 mg orally daily) for 5 years, a sequential strategy of letrozole for 2 years followed by tamoxifen for 3 years, or the reverse sequence. After a median follow-up of 8.1 years, 1022 distant recurrences were observed. Details of the study have been reported previously. [11] [12] [13] 17 All patients provided written informed consent. Ethics committees and relevant health authorities approved the protocol. Tumor samples were collected retrospectively in accordance with institutional guidelines and national laws. The International Breast Cancer Study Group Biological Project Working Group approved this investigation.
Tumor Sequencing and Variant Calling
Library preparation, hybridization-based capture, and nextgeneration sequencing were performed using Foundation Medicine's T5-targeted panel of 287 known cancer genes in a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited laboratory using a previously published method (eTable 1 in the Supplement).
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Samples with a minimum median exon depth of coverage of 150 × were eligible for analysis. After filtering for known germline variants in publicly available databases, only alterations predicted with the accredited variant annotation pipeline were used in these analyses.
These alterations were annotated as known, likely, ambiguous, or unknown. To reduce false-positives, only alterations annotated as known or likely to be pathogenic were included for subsequent analyses as driver alterations. All sequencing and annotation were done without knowledge of patients' treatment assignments or outcomes.
extracted from formalin-fixed, paraffin-embedded archival tumor samples, 938 patients were selected, using a sampling plan identifying all patients having a distant recurrence and a stratified random sampling of those without recurrence ( 
Statistical Analysis
At the design stage, we estimated that, with 350 (10%) distant recurrence events in the eligible cohort and a sampling fraction of 0.10 for a total sample size of 700 patient samples, there would be 80% power to detect hazard ratios (HRs) for association of driver alterations with distant recurrence-free interval of 1.5 for alteration prevalence of 20%, and HR of 2.0 for alteration prevalence of 5%, with nominal α = .05 tests.
20
The primary end point of interest was distant recurrencefree interval, defined as time from randomization to recurrence at a distant site. Patients without distant recurrence were censored at the date of last follow-up or death. Driver alterations were categorized as present or absent (for short variants, as mutated vs wild type; for amplifications, as amplified vs nonamplified). Because oncogenic driver mutations in PIK3CA cluster in distinct functional protein domains, 21 we annotated PIK3CA mutations by affected protein domain: kinase or helical domain mutations. PIK3CA mutations not affecting kinase or helical protein domains were uncommon, less well described, and annotated as other. Exploratory analyses by previously described PIK3CA mutation hotspots (N345, C420, P539, E542, E545, E546, H1047) were performed.
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The generalized Horvitz-Thompson weighted method (inverse probability weighting) was applied to all analyses using the sample weights previously described. 23 For clinicopathologic associations, weighted χ 2 tests were used for categorical variables (age, tumor size, nodal status, and grade) and weighted t tests were used for Ki-67 (percent). Pairwise associations were investigated without sampling weights, characterized by odds ratios and using Fisher exact test to generate P values; multiple testing correction using the BenjaminiHochberg method was applied using a false discovery rate of less than 0.2. For the remainder of the analyses, we deemed an unadjusted, 2-sided value of P < .05 to be significant. Weighted Cox proportional hazards regression models adjusted for treatment arm were used to determine prognostic associations. For each driver alteration, models were adjusted for treatment arm and included the following variables: age, tumor size, nodal status, and grade. Treatment-by-PIK3CA genotype interactions were used to assess the outcome of monotherapy in tumors with or without a kinase or helical domain PIK3CA mutation (both wild-type and other PIK3CA mutations). Hazard ratios and 95% CIs were generated using robust SEs, with a Wald test for significance. Weighted KaplanMeier curves were generated for visualization purposes. Subpopulation treatment effect pattern plot (STEPP) 24 methodology was used in exploratory analyses to illustrate the association between Ki-67 level, PIK3CA mutation status, and disease outcome. All statistical analyses were prespecified. We used R software, version 3.3.1 (R Foundation) and Stata, version 14 (StataCorp) for the statistical analyses. Nineteen driver alterations had a prevalence of 5% or greater, including 9 genes with recurrent mutations and 10 genes with recurrent focal amplifications ( Figure 2 ; eTable 3intheSupplement). PIK3CA mutations were the most common (49%), followed by CCND1 (Entrez 595) amplifications (17%), and TP53 (Entrez 7157) short-variants (15%). PIK3CA-mutated tumors were commonly coaltered (76%) and exhibited heterogeneous coalteration partners (eFigures 1, 2, and 3 in the Supplement). Coalteration frequencies by PIK3CA genotype were similar, with the exception of amplifications on chromosome 11q13, which were significantly more common in wildtype tumors (eFigure 4 in the Supplement). No identifiable driver alteration was identified in 5.7% of patient samples. There was a mean of 4 driver alterations (range, 0-15; interquartile range, 2-6) per tumor. Driver mutations were uncommon for AKT1 (Entrez 207) (4%), ERBB2 (Entrez 2064) (2%), and ESR1 (Entrez 2099) (0%). There were no recurrent structural rearrangements.
Association With Clinicopathologic Characteristics
The associations between driver alterations and clinicopathologic variables are summarized (eFigures 5 and 6 and eTable 4intheSupplement PIK3CA  TP53  MAP3K1  GATA3  CDH1  PTPN11  MAP2K4  SPEN  PTEN  CCND1  FGF19  FGF3  FGF4  MYC  ZNF703  FGFR1  EMSY  KAT6A  ERBB2  GNAS  ZNF217 Only somatic driver alterations with a weighted frequency of 4% or greater in the whole cohort are displayed. All percentages shown are weighted frequencies with the exception of estrogen receptor (ER) and progesterone receptor (PR) expression. Luminal-like status was determined using the 
Associations With Prognosis
We evaluated associations between frequent driver alterations (≥5% frequency) and prognosis in both univariate and multivariable models ( Figure 3) . In univariate analysis, PIK3CA mutations were significantly associated with reduced risk of distant recurrence (HR, 0.57; 95% CI, 0.38-0.85; P = .006).
Analysis of PIK3CA mutations by protein domain vs wildtype PIK3CA demonstrated favorable outcomes for all subgroups (kinase domain, helical domain, and other) (eTable 6 in the Supplement). Conversely TP53 mutations (HR, 1.92; 95% CI, 1.21-3.04; P = .006), 11q13 amplifications (HR, 2.14; 95% CI, 1.36-3.37; P = .001), and 8p11 amplifications (HR, 3.02; 95% CI, 1.88-4.84; P < .001) were associated with significantly increased risk of distant recurrence (eFigure 8 in the Supplement). In multivariable analysis adjusting for age, tumor size, nodal status, and grade, only 11q13 amplifications (HR, 1.72; 95% CI, 1.12-2.64; P = .01) and 8p11 amplifications (HR, 2.00; 95% CI, 1.25-3.21; P = .004) remained statistically significant. Increasing number of somatic driver alterations per tumor was also associated with worse outcomes in both univariate (HR, 1.18; 95% CI, 1.11-1.25; P < .001) and multivariable (HR, 1.11; 95% CI, 1.04-1.19; P = .002) analysis.
Interaction With Treatment: Letrozole vs Tamoxifen
We next investigated whether PIK3CA mutations were associated with a significant treatment interaction. Consistent with our hypothesis, patients with tumors harboring a PIK3CA mutation (kinase or helical, n = 114) derived a greater magnitude of benefit with adjuvant letrozole over tamoxifen (HR, 0.18; 95% CI, 0.06-0.50) than patients whose tumors did not (n = 184) (HR, 1.26; 95% CI, 0.65-2.45; P interaction = .002) (Figure 4 ;e T a b l e7i nt h eSupplement). Further sensitivity analysis by PIK3CA mutation hotspot demonstrated similar results (eTable 8 in the Supplement). Of these patients, 36% were node-positive and 25% had received adjuvant chemotherapy. Patients whose tumors harbored a kinase or helical domain PIK3CA mutation and received letrozole monotherapy had an excellent prognosis, with an estimated 5-year distant recurrence-free proportion of 99% (95% CI, 98%-99%). A statistically significant difference in treatment effect (P interaction = .01) was also observed in the subgroup of no chemotherapy.
Higher Ki-67 levels have been reported to be predictive of increased benefit to adjuvant letrozole. 25 As an exploratory analysis, we investigated the association between Ki-67 level and the presence of kinase/helical domain PIK3CA mutations as predictive biomarkers. 25 In a Cox proportional hazards multivariable model that included adjustment for Ki-67 level, the treatment interaction with PIK3CA mutation status remained statistically significant (P = .03) (eTable 9 in the Supplement). We further performed a STEPP analysis to examine the association between Ki-67 level as a continuous variable and disease outcome, adjusted for PIK3CA mutation status (eFigure 9 in the Supplement). As illustrated, the increased magnitude of benefit of adjuvant letrozole appeared to be driven by PIK3CA mutation status independent of Ki-67 levels.
Discussion
In this analysis of primary tumor samples from postmenopausal women with ER+/HER2− BC from the randomized phase 3 BIG 1-98 study, we have described the landscape of driver alterations, their association with clinicopathologic factors, and prognostic associations for distant recurrence-free interval. Furthermore, we report that patients with tumors harboring kinase or helical domain PIK3CA mutations derived a greater magnitude of benefit with letrozole over tamoxifen therapy and 
Favors Tamoxifen
A and B, Weighted cumulative incidence curves demonstrating the prognostic effect of letrozole or tamoxifen monotherapy on the risk of distant recurrence by PIK3CA mutation status. Number of events indicates the observed number of distant recurrences per subgroup. The 5-year estimates for distant recurrence and 95% CIs were calculated with the use of sampling weights. C, Hazard ratio (HR) for letrozole monotherapy vs tamoxifen monotherapy according to PIK3CA mutation status. These data were derived with a weighted univariate Cox proportional hazards regression model. The interaction P value represents the interaction between PIK3CA mutation status and treatment benefit. The observed number of patients (number of events) was 114 (24) for the PIK3CA mutation-positive group and 184 (47) for PIK3CA mutation-negative group.
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Somatic Driver Alterations in Hormone Receptor-Positive, HER2-Negative Breast Cancer had long-term freedom from distant recurrence. To our knowledge, this is the first study to report a DNA-based predictive biomarker in this setting. Given that relapse from ER+/HER2− disease is the major cause of death from BC, our results are important in understanding the biological mechanisms of aggressive ER+/HER2− disease. Similar to previous studies in heterogeneously selected BCs, we observed a diverse driver alteration landscape. 1, 3, 4, 26 PIK3CA mutations were the most common, followed by TP53 mutations, with many other mutations occurring at lesser frequencies. One difference in the BIG 1-98 data set was that recurrent mutations in PTPN11 and SPEN were detected, which have only recently been described in BC, With respect to risk of distant recurrence, TP53 mutations and amplifications on 11q13 and 8p11 were associated with significantly poorer outcome. This outcome has been shown previously, 3,4,30,31 with higher proliferation rates and promotion of endocrine resistance. Our unique data set lends support to their prognostic implications in early-stage postmenopausal ER+ BC. A novel finding was that progressively poorer outcomes were observed as numbers of driver alterations increased. This has been shown previously in myelodysplasia 33 and suggests that driver alterations have significant implications even if they are subclonal, consistent with an adverse prognostic role described for intratumor heterogeneity 34 and the presence of subclonal drivers 35 observed in other cancer types.
As expected, tumor PIK3CA mutations were associated with a better outcome but did not remain significant in the multivariable model owing to associations with good prognosis variables. 15, 22, 32, 36 Our data, however, highlight the diversity in coexisting driver alterations with PIK3CA. This variation may result in a heterogeneous clinical phenotype but also suggests the need for future clinical studies in this setting to take genomic context into consideration. We also report the novel finding of a predictive role for PIK3CA genotype in identifying patients who derived greater benefit from 5 years of letrozole adjuvant therapy. In patients with tumors harboring kinase/helical PIK3CA mutations, the estimated proportion of patients without a distant recurrence at 5 years for those who received 5 years of letrozole was 99%. This finding is biologically plausible 15,16 and important as PIK3CA mutations are enriched in ER+/HER2− BC. Further studies to establish the exact mechanisms underlying this observation and validate our finding are warranted. If confirmed, PIK3CA genotyping could be easier to implement in the clinic because of the ease of interpreting a binary result (mutated vs not) and reproducibility of a DNA-based test. Higher Ki-67 levels have previously been reported to be predictive of increased benefit to adjuvant letrozole. 25 However, to our knowledge, no prior study has established the interaction between Ki-67 and PIK3CA mutation status on treatment effect comparing letrozole with tamoxifen. The interaction between PIK3CA status and treatment assignment remained statistically significant in a multivariable model, suggesting the genotype had independent predictive value even after adjustment for Ki-67 level. Moreover, using STEPP analysis (eFigure 9 in the Supplement), the magnitude of increased benefit of letrozole at higher Ki-67 levels appeared to be limited to the PIK3CA-mutated subgroup, suggesting that PIK3CA genotype provided additional predictive value above Ki-67 alone. Although retrospective, our data are strengthened by the use of a clinical trial data set with prospective treatment randomization and robust recurrence data with a median follow-up of 8 years. The strength of biomarker analyses in this context has been previously reported.
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Limitations
Our study had a limited ability to examine subgroups and infrequent driver alterations. While we used only 20% of the samples from the total trial cohort, the sampling design and weighted analysis is a financially efficient, wellaccepted, and methodologically sound approach for a biomarker study (eTable 2 in the Supplement).
23,38 For example, the lobular histologic subtype has also been reported to derive increased benefit from adjuvant letrozole. 39 While lobular carcinomas have been recently reported to harbor high frequencies of PIK3CA mutations, 40 our study was underpowered to confirm that PIK3CA mutations are independently driving this outcome in the lobular carcinomas.
Conclusions
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.Characteristics of the Entire Eligible BIG 1-98 Cohort and of the Analysis Population
Characteristics of the entire eligible BIG 1-98 cohort and of the analysis population, which was based on selection of all patients experiencing a distant recurrence and a stratified random sampling of the patients' not experiencing recurrence, for whom DNA was assessable. Unweighted (as sampled) and weighted (to correct for over-sampling of recurrences) percentages of the analysis population are provided. Luminal-like status was determined using the published St. 
